Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemo in Neoadjuvant Cervical Cancer
NCT06986057Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in Cervical Cancer (CC), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective Response Rate (CR/PR) at 4 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06986057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986057.